News
04 Mar 2013
Crystal Pharmatech and Particle Sciences Form a US-China Pharmaceutical CRO Partnership
04 Mar 2013
en
Cranbury, NJ, May 14, 2024 – Crystal Bio, an innovative biologics analytical division of Crystal Pharmatech, is delighted to announce the appointment of Dr. Ye Gu as Co-founder, Chief Technology Officer, and Head of USA Business Development. Dr. Gu brings over 16 years of distinguished experience in biologics R&D and a robust track record of leadership in the biotechnology industry.
Dr. Gu boasts a remarkable 16-year career within the biopharmaceutical realm. As a seasoned protein biochemist, Dr. Gu has spearheaded numerous projects across Discovery, Pre-clinical, and Clinical stages of research and development. Her comprehensive expertise encompasses all facets of biotherapeutics discovery and development, from hits generation and screening to candidate selection, production and advanced protein characterization. Prior to joining Crystal Bio, Dr. Gu held pivotal leadership positions in various biotech companies, where she oversaw process and analytical development as well as CMC operations. Before her tenure in biotech, she spent over a decade as group head, project leader and scientist in large pharmaceutical companies Boehringer Ingelheim and Vertex. Her portfolio spans broadly across biologics discovery, development, and CMC, with experience covering diverse biologics modalities such as antibodies, bi/tri-specifics, fusion proteins, ADCs, cell, and in vivo mRNA (-LNP) therapy.
Dr. Gu earned a Ph.D. in Analytical Chemistry under the mentorship of Prof. Barry Karger at Northeastern University, following a B.S. in Materials Engineering and Chemistry from the University of Science & Technology of China. Her work has not only led to impactful publications and patents but has also established her as a reputable leader in collaborative endeavors with research organizations and innovation companies.
“Ye’s exceptional leadership and profound knowledge in biologics R&D will be invaluable as we continue to innovate and expand,” expressed by Dr. Alex Chen, Chairman and CEO of Crystal Pharmatech. “Her vision for technology advancement and her strategic approach are exactly what Crystal Bio needs at this pivotal time.”
“We are thrilled to welcome Dr. Ye Gu to our leadership team,” said Crystal Bio’s Co-Founder and CSO, Dr. Shiaw-Lin (Billy) Wu. “Her extensive experience and strategic vision will be instrumental as we continue to drive innovation and bring advanced analytical services for biotech and pharma companies developing biologics.”
Dr. Gu expressed her enthusiasm about her new role, stating, “I am excited to contribute to Crystal Bio’s mission of advancing biologics analytical techniques. I look forward to driving our technology platforms forward and expanding our impact on the market.”
